Overview

Achieve robust activation and expansion of human T cells for use in clinical applications–without the use of magnetic beads, feeder cells, or antigens.

This product's gentle activation stimulus ensures a high viability of activated T cells, which can be further expanded in ImmunoCult™-XF—a high-performance T cell expansion medium manufactured under relevant cGMP regulations and guidelines. ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator consists of soluble antibody complexes that bind to and cross-link CD3, CD28, and CD2 cell surface ligands, providing the required primary and co-stimulatory signals for T cell culture and activation.

ImmunoCult™ Human CD3/CD28/CD2 T Cell Activator is designed for cell therapy clinical research applications, qualified for use as an ancillary material (AM) following the framework outlined in USP<1043> and/or PH. EUR. 5.2.12. STEMCELL can work with you to qualify this reagent as an AM under an approved Investigational New Drug (IND) application, Biological Licensing Application (BLA), or Clinical Trial Application (CTA). 

Contains
- Anti-human CD3 monospecific antibody complex
- Anti-human CD28 monospecific antibody complex
- Anti-human CD2 monospecific antibody complex
- Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20
 

Subtype
Supplements
 

Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
 

Species
Human
 

Application
Activation, Cell Culture, Expansion
 

Brand
ImmunoCult
 

Area of Interest
Cancer, Immunology, Cell Therapy Development

Product Advantages

- Activate T cells with confidence for use in clinical applications using activators produced under relevant cGMPs

- Achieve robust activation without the use of magnetic beads, feeder cells, or antigens

- Maintain a high viability of activated and expanded T cells with gentle activation stimulus

- Rely on a highly stable, filter-sterilized soluble reagent

Catalog #: 100-0785

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.